Noxopharm appoints new executive

Latest News

Noxopharm (ASX:NOX) has announced the appointment of Alexander Hunter as its chief commercial officer.

Mr Hunter has 15 years of experience in corporate finance, capital raising, mergers and acquisitions and growth company strategy in Australian and US operating environments, said the company.

He was previously chief financial officer of an ASX-listed energy company and holds an MBA from the University of Southern California Marshall School of Business, a Bachelor of Engineering, and postgraduate qualifications in corporate finance and business law.

The company said Mr Hunter’s skills will add important management strength to its executive team as it embarks on its next phase of growth.

Dr Graham Kelly, Noxopharm CEO and executive chairman said, “The Company’s upcoming period of corporate and business growth stemming from its proposed dual listing in 2020, and emerging opportunities from the development of Veyonda and its planned expanded clinical program, require strengthening of the executive team with a seasoned corporate finance and business executive.

"Alex brings this strength to the Noxopharm team and we are delighted that he is joining the Company at this exciting time. He will draw on his listed company financial and operating experience in Australia and the U.S. to help Noxopharm drive its growth objectives."